{
    "organizations": [],
    "uuid": "9a3b98e264ca97feda925830fa10223a2d23d98d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-beyondspring-qtrly-loss-per-share/brief-beyondspring-qtrly-loss-per-share-0-68-idUSASC09UN5",
    "ord_in_thread": 0,
    "title": "BRIEF-Beyondspring Qtrly Loss Per Share $0.68",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - BeyondSpring Inc:\n* PROVIDES OPERATIONAL UPDATE AND FOURTH-QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS\n* QTRLY LOSS PER SHARE $0.68 * CASH AND CASH EQUIVALENTS WERE $30.6 MILLION AT DEC. 31, 2017, COMPARED TO $40.7 MILLION AT SEPT. 30, 2017\n* BELIEVES HAS SUFFICIENT CASH RESOURCES TO ADVANCE ONGOING CLINICAL TRIALS IN LATE 2018 OR EARLY 2019 AND FIRST HALF OF 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T19:06:00.000+03:00",
    "crawled": "2018-04-04T12:31:21.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "beyondspring",
        "inc",
        "provides",
        "operational",
        "update",
        "financial",
        "result",
        "qtrly",
        "loss",
        "per",
        "share",
        "cash",
        "cash",
        "equivalent",
        "million",
        "compared",
        "million",
        "belief",
        "sufficient",
        "cash",
        "resource",
        "advance",
        "ongoing",
        "clinical",
        "trial",
        "late",
        "early",
        "first",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}